Health
Ultrapotent compound may help treat C. diff, reduce recurrence – Medical Xpress
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Only two antibiotics, vancomycin and fidaxomicin, are FDA approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.
Now, Purdue University innovators have advanced novel compounds they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Preventio…
-
Business18 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News17 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Business22 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business21 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025